Synthesis of micrometer to nanometer CaCO3 particles via mass restriction method in an emulsion liquid membrane process

Sun, Qiang; Deng, Yulin

doi:10.1016/j.jcis.2004.06.013

Cited by 46 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanocomposites possess improved physical, mechanical, and thermal properties over the pristine polymer matrix as well known. The material properties of physically mixed inorganic–polymer composites depend on the content of the inorganic particles, their adhesion to the polymer matrix, the uniformity of particle dispersion, and some other factors 15–19. Numerous previous studies have reported that the resins modified with inorganic particles exhibited great improvements in their mechanical, thermal, and physicochemical properties compared with the pristine resin 18, 20–23.…”

Section: Introductionmentioning

confidence: 99%

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Fleischmann

Cutolo

Genovese

et al. 2012

Arthritis & Rheumatism

350

286

View full text Add to dashboard Cite

Objective. To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.Methods. In this 24-week, double-blind, phase IIb study, patients with RA (n ‫؍‬ 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected subcutaneously every 2 weeks (total of 6 injections) followed by oral tofacitinib at 5 mg twice a day for 12 weeks. The primary end point was the responder rate according to the American College of Rheumatology 20% improvement criteria (ACR20) at week 12.Results. Treatment with tofacitinib at a dose of >3 mg twice a day resulted in a rapid response with significant efficacy when compared to placebo, as indicated by the primary end point (ACR20 response at week 12), achieved in 39.2% (3 mg; P < 0.05), 59.2% (5 mg; P < 0.0001), 70.5% (10 mg; P < 0.0001), and 71.9% (15 mg; P < 0.0001) in the tofacitinib group and 35.9% of patients in the adalimumab group (P ‫؍‬ 0.105), compared with 22.0% of patients receiving placebo. Improvements were sustained at week 24, according to the ACR20, ACR50, and ACR70 response rates as well as classifications of remission according to the 3-variable Disease Activity Score in 28 joints (DAS28) using C-reactive protein and the 4-variable DAS28 using the erythrocyte sedimentation rate. The most common

show abstract

Section: Introductionmentioning

confidence: 99%

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Fleischmann

Cutolo

Genovese

et al. 2012

Arthritis & Rheumatism

350

286

View full text Add to dashboard Cite

show abstract

“…The material properties of physically mixed inorganic-polymer composites depend on the content of the inorganic particles, their adhesion to the polymer matrix, the uniformity of particle dispersion, and some other factors. [15][16][17][18][19] Numerous previous studies have reported that the resins modified with inorganic particles exhibited great improvements in their mechanical, thermal, and physicochemical properties compared with the pristine resin. 18,[20][21][22][23] However, there is no report on PBOZ toughening modified by nano-SiO 2 particles to our best knowledge.…”

Section: Introductionmentioning

confidence: 99%

Study of surface‐functionalized nano‐SiO₂/polybenzoxazine composites

Yan

Fan

et al. 2010

J of Applied Polymer Sci

View full text Add to dashboard Cite

A series of the surface-functionalized nanoSiO 2 /polybenzoxazine (PBOZ) composites was produced, and an attempt was made to improve the toughness of PBOZ material, without sacrificing other mechanical and thermal properties. A benzoxazine functional silane coupling agent was synthesized to modify the surface of nano-SiO 2 particles, which were then mixed with benzoxazine monomers to produce the nano-SiO 2 -PBOZ nanocomposites. The notched impact strength and the bending strength of the nano-SiO 2 -PBOZ nanocomposites increase 40% and 50%, respectively, only with the addition of 3 wt % nano-SiO 2 . At the same load of nano-SiO 2 , the nanoSiO 2 -PBOZ nanocomposites exhibit the highest storage modulus and glass-transition temperature by dynamic viscoelastic analysis. Moreover, the thermal stability of the SiO 2 /PBOZ nanocomposites was enhanced, as explored by the thermogravimetric analysis. The 5% weight loss temperatures increased with the nano-SiO 2 content and were from 368 C (of the neat PBOZ) to 379 C or 405 C (of the neat PBOZ) to 426 C in air or nitrogen with additional 3 wt % nano-SiO 2 . The weight residue of the same nanocomposite was as high as 50% in nitrogen at 800 C. V C 2010Wiley Periodicals, Inc. J Appl Polym Sci 120: [1525][1526][1527][1528][1529][1530][1531][1532] 2011

show abstract

“…[1][2][3][4][5][6] This typical process inspires researchers to employ ELM as reaction media for particle synthesis, i.e., employ the internal water droplets as micro reactors. Such facile and mild method has already been utilized to prepare various materials such as oxalate, [7][8][9] oxide, [10][11][12] cadmium sulfide, [13] phosphate, [14,15] calcium carbonate, [16,17] sulfate [14] and composites. [18][19][20][21] Morphology and size of the particles could be controlled through changing carrier concentration or water-oil ratio for controlling mass transfer rate.…”

Section: Introductionmentioning

confidence: 99%

Formation Mechanism of Zinc Oxalate Particles in the Internal Aqueous Droplets of Emulsion Liquid Membrane

Zhao

Zhang

et al. 2014

Journal of Dispersion Science and Technology

View full text Add to dashboard Cite

We have investigated the formation and evolution of zinc oxalate particles in internal aqueous droplets and their effects of emulsion interface properties. The formation of particles follows an aggregation-controlled mechanism that depends on the size of droplets and surfactant. The size of droplets determines the final shape of the particles by affecting the supersaturation ratio to form rod-like and sheet-like particles. The surfactant adsorbed on the particles changes the wettability, leading to the aggregation of the primary particles at the internal water-oil interface. Moreover, the adsorption can cause a higher level of impurity and defects in as-synthesized particles. This effect could be directly employed to fabricate heterojunction rectifier.

show abstract

Synthesis of micrometer to nanometer CaCO3 particles via mass restriction method in an emulsion liquid membrane process

Cited by 46 publications

References 13 publications

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Study of surface‐functionalized nano‐SiO₂/polybenzoxazine composites

Formation Mechanism of Zinc Oxalate Particles in the Internal Aqueous Droplets of Emulsion Liquid Membrane

Contact Info

Product

Resources

About

Synthesis of micrometer to nanometer CaCO3 particles via mass restriction method in an emulsion liquid membrane process

Cited by 46 publications

References 13 publications

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Study of surface‐functionalized nano‐SiO2/polybenzoxazine composites

Formation Mechanism of Zinc Oxalate Particles in the Internal Aqueous Droplets of Emulsion Liquid Membrane

Contact Info

Product

Resources

About

Study of surface‐functionalized nano‐SiO₂/polybenzoxazine composites